Chronic Lymphocytic Leukemia (CLL)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Waldenström's Macroglobulinemia (WM)
Investigational drug(s) / intervention(s)
Routine care as per site standard.
Routine care as per site standard.: Physician's choice according to patient's needs.
Study summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years
* Confirmed diagnosis of the respective NHL
* If patient is alive: signed written informed consent
* For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.
* For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.
Exclusion Criteria:
* No systemic therapy for respective lymphoid malignancy.
Primary outcome measure(s)
Course of treatment (treatment reality) — 5 years Documentation of anamnestic data and therapy sequences. Documentation of anamnestic data and therapy sequences
Trial sites (1)
Facility
City
Region
Status
Praxis für Interdisziplinäre Hämatologie und Onkologie
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.